2025
Connectome-based predictive modeling of early and chronic psychosis symptoms
Foster M, Ye J, Powers A, Dvornek N, Scheinost D. Connectome-based predictive modeling of early and chronic psychosis symptoms. Neuropsychopharmacology 2025, 1-9. PMID: 40016363, DOI: 10.1038/s41386-025-02064-9.Peer-Reviewed Original ResearchConnectome-based predictive modelingPositive and Negative Syndrome ScalePsychosis symptomsSymptom networksSymptom severityBrain networksNeural correlates of CPResting-state functional magnetic resonance imagingFunctional magnetic resonance imagingNegative Syndrome ScaleIdentified group differencesPredicted effect sizeCorrelates of CPGeneral psychopathologyNegative symptomsPositive symptomsSyndrome ScaleFrontoparietal networkNeural correlatesVirtual lesion analysisGroup differencesConnectivity changesEffect sizeLesion analysisLongitudinal studyEmergence and dynamics of delusions and hallucinations across stages in early psychosis
Mourgues-Codern C, Benrimoh D, Gandhi J, Farina E, Vin R, Zamorano T, Parekh D, Malla A, Joober R, Lepage M, Iyer S, Addington J, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Stone W, Mathalon D, Perkins D, Walker E, Cannon T, Woods S, Shah J, Powers A. Emergence and dynamics of delusions and hallucinations across stages in early psychosis. Biological Psychiatry 2025 PMID: 40020853, DOI: 10.1016/j.biopsych.2025.02.891.Peer-Reviewed Original ResearchFirst-episode psychosis patientsSymptom patternsNorth American Prodrome Longitudinal StudyPositive symptoms of psychosisSymptoms of psychosisCHR-P samplesEarly intervention programsPositive symptomsDelusional ideationPsychosis patientsEarly psychosisCHR-PNeural mechanismsDelusionsHallucination onsetHallucinationsPsychosisBaseline assessmentLongitudinal studyIntervention programsSymptomsTime courseParticipantsIdeationOnsetDepth inversion illusion and its relationship to positive symptoms in clinical and non-clinical voice hearers
Erickson M, Li C, Bansal S, Waltz J, Corlett P, Gold J. Depth inversion illusion and its relationship to positive symptoms in clinical and non-clinical voice hearers. Cognitive Neuropsychiatry 2025, ahead-of-print: 1-12. PMID: 39969991, DOI: 10.1080/13546805.2025.2467974.Peer-Reviewed Original ResearchPositive symptomsHealthy control subjectsAssociated with positive symptomsEnhanced perception of stimuliDepth inversion illusionsNon-clinical voice hearersVisual illusionsPerception of stimuliIllusion taskSymptom severityModulation of sensory informationPsychiatric illnessInversion illusionsIllusion perceptionVoice hearersMental illnessEnhanced perceptionSensory informationSymptomsControl subjectsPSZIllnessIllusionSchizophreniaDelusionsCELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS
Wang *, Chen X, Tian Y, Yu Z, Chen D, Xiu M, Kosten T, Zhang X. CELECOXIB ADDED TO RISPERIDONE FOR DEPRESSIVE SYMPTOMS IN FIRST-EPISODE AND DRUG NAÏ VE SCHIZOPHRENIA: PHARMACOGENETIC IMPACT OF BDNF GENE POLYMORPHISMS. The International Journal Of Neuropsychopharmacology 2025, 28: i158-i159. PMCID: PMC11815116, DOI: 10.1093/ijnp/pyae059.274.Peer-Reviewed Original ResearchHamilton Depression Rating ScaleBrain-derived neurotrophic factorPositive and Negative Syndrome ScaleBrain-derived neurotrophic factor serum levelsBrain-derived neurotrophic factor levelsSchizophrenia patientsTreatment of depressionDepressive symptomsPositive symptomsFirst-episodeSCZ patientsHamilton Depression Rating Scale total scoreBrain-derived neurotrophic factor systemComorbid major depressive disorderTreatment response to antidepressantsTotal scoreEarly stages of schizophreniaBrain-derived neurotrophic factor polymorphismsBrain-derived neurotrophic factor genotypePathogenesis of depressive symptomsBrain-derived neurotrophic factor gene polymorphismImprove treatment of depressionBrain-derived neurotrophic factor signalingHealthy controlsAmerican Journal of PsychiatryRevisiting the Defeatist Performance Belief Scale in Adults With Schizophrenia and Youth at Clinical High-Risk for Psychosis: A Comprehensive Psychometric Analysis
Luther L, Ahmed A, Grant P, Granholm E, Gold J, Williams T, Pratt D, Holden J, Walker E, Arnold L, Ellman L, Mittal V, Zinbarg R, Silverstein S, Corlett P, Powers A, Woods S, Waltz J, Schiffman J, Strauss G. Revisiting the Defeatist Performance Belief Scale in Adults With Schizophrenia and Youth at Clinical High-Risk for Psychosis: A Comprehensive Psychometric Analysis. Schizophrenia Bulletin 2025, sbae220. PMID: 39749462, DOI: 10.1093/schbul/sbae220.Peer-Reviewed Original ResearchDefeatist performance beliefsSchizophrenia spectrum groupClinical high riskNegative symptomsFactor structureCognitive model of negative symptomsMechanisms of negative symptomsModel of negative symptomsNegative symptom improvementNegative symptoms treatmentPhase of psychosisFactor analysisComprehensive psychometric analysisConfirmatory factor analysisExploratory factor analysisPositive symptomsCHR samplesPerformance beliefsMeasurement invarianceDiscriminant validityConvergent validityPsychometric propertiesCognitive modelUnidimensional modelBeliefs Scale
2024
Empathic disequilibrium in schizophrenia: An individual participant data meta-analysis
Shalev I, Shamay-Tsoory S, Montag C, Assaf M, Smith M, Eran A, Uzefovsky F. Empathic disequilibrium in schizophrenia: An individual participant data meta-analysis. Journal Of Psychiatric Research 2024, 181: 253-261. PMID: 39637716, DOI: 10.1016/j.jpsychires.2024.11.045.Peer-Reviewed Original ResearchCognitive empathySchizophrenia diagnosisEmotional empathyCognitive components of empathyComponents of empathyInterpersonal Reactivity IndexSocial cognitive constructsSchizophrenia phenomenologyPositive symptomsCognitive constructsEmpathy measuresSchizophreniaSocial difficultiesCognitive componentsEmpathyReactivity indexData meta-analysisParticipant data meta-analysisMeta-analysisIndividual participant data meta-analysisResponse surface analysisSymptomsIndividual-participant data meta-analysisStable indexInterpersonalNeighborhood ethnoracial diversity and positive psychotic symptoms among youth at high-risk and healthy comparisons
Ku B, Yuan Q, Haardörfer R, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Woods S, Druss B, Walker E, Anglin D. Neighborhood ethnoracial diversity and positive psychotic symptoms among youth at high-risk and healthy comparisons. Psychiatry Research 2024, 342: 116222. PMID: 39378539, PMCID: PMC11617269, DOI: 10.1016/j.psychres.2024.116222.Peer-Reviewed Original ResearchHealthy comparisonPositive symptomsCHR-PPeer victimizationNorth American Prodrome Longitudinal StudyScale of Prodromal SymptomsAttenuated positive symptomsPositive psychotic symptomsClinical high riskFewer life eventsAssociated with schizophreniaEthnoracial diversityPsychotic symptomsHigh riskPrevent psychosisDepressive symptomsStructural equation modelingLife eventsProdromal symptomsPsychosisDiscriminatory experiencesEthnoracial minoritiesSocial determinantsNeighborhood povertyEthnoracial groupsDiffering Pattern of Mismatch Negativity Responses in Clinical and Nonclinical Voice Hearers Challenge Predictive Coding Accounts of Psychosis
Erickson M, Bansal S, Li C, Waltz J, Corlett P, Gold J. Differing Pattern of Mismatch Negativity Responses in Clinical and Nonclinical Voice Hearers Challenge Predictive Coding Accounts of Psychosis. Biological Psychiatry Global Open Science 2024, 5: 100394. PMID: 39526022, PMCID: PMC11550737, DOI: 10.1016/j.bpsgos.2024.100394.Peer-Reviewed Original ResearchHealthy comparison subjectsReduced mismatch negativityPrediction error signalsPositive symptomsMismatch negativityDeviant typesPredictive coding accountPresence of hallucinationsMismatch negativity paradigmAuditory memory tracesComparison subjectsCoding accountMemory tracesPsychiatric illnessMMN responseVoice hearersRepetitive positioningError signalDuration conditionsHallucinationsHigher-levelDMMNDifferent patternsSymptomsPSZEfficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data
Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data. Schizophrenia Research 2024, 272: 1-11. PMID: 39142215, DOI: 10.1016/j.schres.2024.07.035.Peer-Reviewed Original ResearchClinical Global Impression ScaleSchizophrenia spectrum disordersPositive and Negative Syndrome ScaleBaseline PANSS total scoreAntipsychotic polypharmacyPANSS total scoreTotal scorePositive symptomsPsychotic patientsPositive and Negative Syndrome Scale positive symptom subscaleNegative symptom subscale scoreSubgroup of psychotic patientsBaseline positive symptomsExtrapyramidal side effectsNegative Syndrome ScalePositive symptom subscaleSecond-generation antipsychoticsGlobal Impression ScaleModerators of efficacySeverely psychotic patientsStudy-level moderatorsStudy discontinuationSymptom subscale scoresAntipsychotic monotherapySyndrome ScaleDisentangling negative and positive symptoms in schizophrenia and autism spectrum disorder
Corbera S, Wexler B, Bell M, Pittman B, Pelphrey K, Pearlson G, Assaf M. Disentangling negative and positive symptoms in schizophrenia and autism spectrum disorder. Schizophrenia Research 2024, 271: 1-8. PMID: 39002525, PMCID: PMC11384336, DOI: 10.1016/j.schres.2024.07.002.Peer-Reviewed Original ResearchAutism spectrum disorderPositive and Negative Syndrome ScaleAutism Diagnostic Observation Schedule-GenericExperiential negative symptomsPositive symptomsNegative symptomsExploratory factor analysisSpectrum disorderNegative Syndrome ScaleTarget negative symptomsSyndrome ScaleDiscriminant function analysisSZ relativesAssociated with quality of lifeSchizophreniaSocial skillsSocial functioningDiagnostic classificationAutismFactor analysisAssociated with qualityPredictor of diagnosisSymptomsDisordersQuality of lifeThe Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis
Cowan H, Williams T, Mittal V, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshevan M, Perkins D, Mathalon D, Stone W, Woods S, Walker E. The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 1295-1309. PMID: 38728417, PMCID: PMC11548925, DOI: 10.1093/schbul/sbae042.Peer-Reviewed Original ResearchAttenuated psychotic symptomsClinical high riskPsychotic symptomsGeneral factorBifactor modelPsychosis riskPsychotic disordersPresence of attenuated psychotic symptomsFunctional impairmentConversion to psychotic disordersAssessment of psychosis riskPositive symptom factorNon-psychotic symptomsPsychosis-Risk SyndromesAssociated with depressive symptomsCHR participantsPositive symptomsCHR statusCHR samplesSymptom varianceTransdiagnostic assessmentInternalizing symptomsSymptom factorsPreregistered replicationDepressive symptomsCross‐cohort replicable resting‐state functional connectivity in predicting symptoms and cognition of schizophrenia
Zhao C, Jiang R, Bustillo J, Kochunov P, Turner J, Liang C, Fu Z, Zhang D, Qi S, Calhoun V. Cross‐cohort replicable resting‐state functional connectivity in predicting symptoms and cognition of schizophrenia. Human Brain Mapping 2024, 45: e26694. PMID: 38727014, PMCID: PMC11083889, DOI: 10.1002/hbm.26694.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingNegative symptomsFunctional connectivityCognitive impairmentPrediction of negative symptomsResting-state functional connectivityAssociated with reduced cognitive functionDebilitating mental illnessHealthy controlsPredicting functional connectivityEarly adulthood onsetPositive symptomsNeural underpinningsSchizophreniaCognitive functionSensorimotor networkPredicting symptomsMental illnessConnectivity patternsClinical interventionsMagnetic resonance imagingAdulthood onsetSymptomsImpairmentResonance imagingRace/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis
Ruiz‐Yu B, Le T, Weintraub M, Zinberg J, Addington J, O'Brien M, Walsh B, Friedman‐Yakoobian M, Auther A, Cornblatt, Domingues I, Cannon T, Miklowitz D, Bearden C. Race/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis. Early Intervention In Psychiatry 2024, 18: 981-990. PMID: 38676463, PMCID: PMC11512687, DOI: 10.1111/eip.13541.Peer-Reviewed Original ResearchClinical high riskNegative symptomsFamily therapyRandomized trial of family-focused therapyGlobal functioningEffect of race/ethnicityNHW participantsTrial of family therapyFamily-focused therapyParental educationAssociated with greater improvementSociodemographic factorsSocioeconomic statusPositive symptomsPsychosocial treatmentsPsychosocial functioningHigher parental educationFollow-up measurementsHigh riskInfluence of race/ethnicityGreater improvementRandomized trialsTreatment outcomesPsychosisPredictors of outcomeThe relationship between childhood trauma, psychotic symptoms, and cognitive schemas in patients with schizophrenia, their siblings, and healthy controls: results from the EU-GEI study.
Üçok A, Noyan H, Gülöksüz S, Saka M, Alptekin K, Atbaşoğlu C, Akturan E, Karadayı G, Baran Tatar Z, Akdede B, Binbay T, Altınyazar V, Ulaş H, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Şahin Cankurtaran E, Ulusoy Kaymak S, Rutten B, van Os J. The relationship between childhood trauma, psychotic symptoms, and cognitive schemas in patients with schizophrenia, their siblings, and healthy controls: results from the EU-GEI study. Psychological Medicine 2024, 54: 2414-2425. PMID: 38606591, DOI: 10.1017/s0033291724000540.Peer-Reviewed Original ResearchNegative cognitive schemasChildhood traumaCognitive schemasPsychotic symptomsEU-GEIEmotional abuseBrief Core Schema ScalesEU-GEI studySubthreshold psychotic experiencesSubtypes of traumaChildhood emotional abuseChildhood Trauma QuestionnaireNon-clinical populationsHealthy controlsNegative schemasPositive symptomsPersecutory delusionsPsychotic experiencesSchema ScaleTrauma QuestionnaireChildhood abuseSymptom severitySchizophreniaSexual abuseAbusePlasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies
Byrne J, Healy C, Föcking M, Heurich M, Susai S, Mongan D, Wynne K, Kodosaki E, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, Jeffries C, Perkins D, Cotter D. Plasma complement and coagulation proteins as prognostic factors of negative symptoms: An analysis of the NAPLS 2 and 3 studies. Brain Behavior And Immunity 2024, 119: 188-196. PMID: 38555993, DOI: 10.1016/j.bbi.2024.03.049.Peer-Reviewed Original ResearchNegative symptomsDepressive symptomsScale of Psychosis-risk SymptomsMeasures of negative symptomsNorth American Prodrome Longitudinal Study 2Psychosis-risk symptomsClinical high riskPrognostic factorsLongitudinal Study 2Positive symptomsNAPLS 2Psychotic disordersAntipsychotic usePsychotic experiencesCannabis useSuicidal ideationAntidepressant useStudy 2Regulation groupQuality of life of individualsGroup factorsCurrent treatment optionsDemographic prognostic factorsPsychosisCoagulation proteinsDo metacognitive therapies for schizophrenia-spectrum disorders work? A meta-analytic investigation.
Melville G, Hoffman M, Pollock A, Kurtz M. Do metacognitive therapies for schizophrenia-spectrum disorders work? A meta-analytic investigation. Psychological Medicine 2024, 54: 1510-1518. PMID: 38509837, DOI: 10.1017/s0033291724000564.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersMetacognitive therapyNegative symptomsSocial cognitionEfficacy of metacognitive therapyMeta-cognitive therapySingle-session interventionSmall-to-moderate effectsDuration of illnessAntipsychotic dosagePositive symptom outcomesPositive symptomsIllness insightPotential moderatorsPsychosocial functioningSymptom outcomesCognitive biasesSecondary symptomsControlled trialsClinical insightsSample differencesCognitionSmall effectsSymptomsDisordersAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsCorrelation of allostatic load and perceived stress with clinical features in first-episode schizophrenia
Zhou Y, Wang L, Yang K, Huang J, Li Y, Li W, Zhang P, Fan F, Yin Y, Yu T, Chen S, Luo X, Tan S, Wang Z, Feng W, Tian B, Tian L, Li C, Tan Y. Correlation of allostatic load and perceived stress with clinical features in first-episode schizophrenia. Journal Of Psychiatric Research 2024, 172: 156-163. PMID: 38382239, DOI: 10.1016/j.jpsychires.2024.02.025.Peer-Reviewed Original ResearchFirst-episode schizophreniaCalgary Depression Scale for SchizophreniaPositive and Negative Syndrome ScalePerceived stressPositive symptomsAllostatic loadPSS scoresSeverity of positive symptomsClinical features of schizophreniaNegative Syndrome ScaleFeatures of schizophreniaChronic physiological stressAssociated with depressive symptomsEtiology of schizophreniaAssess subjective stressOccurrence of schizophreniaHealthy controlsPerceived Stress Scale-14Clinical featuresCDSS scoresSyndrome ScaleDepressive symptomsSchizophreniaSubjective stressStressor typeNeuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia
Preller K, Scholpp J, Wunder A, Rosenbrock H. Neuroimaging Biomarkers for Drug Discovery and Development in Schizophrenia. Biological Psychiatry 2024, 96: 666-673. PMID: 38272287, DOI: 10.1016/j.biopsych.2024.01.009.Peer-Reviewed Original ResearchNMDA receptor hypofunctionPsychosis spectrum disordersNeuroimaging data acquisitionField of neuroimagingNegative symptomsPharmacological neuroimagingPositive symptomsReceptor hypofunctionPsychotic disordersNeuroimaging resultsSpectrum disorderNeuroimaging technologiesNeuroimaging biomarkersSchizophreniaNeuroimagingPathophysiology of symptomsDrug developmentDecades of researchTarget engagementClinical drug developmentPredictive biomarkersDisordersSymptomsHealthy volunteersDose selectionThe impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction
Hazan H, Ferrara M, Riley S, Li F, Zhou B, Kline E, Gibbs-Dean T, Karmani S, Tayfur S, Tek C, Keshavan M, Srihari V. The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction. Schizophrenia Research 2024, 264: 457-461. PMID: 38266513, PMCID: PMC10923115, DOI: 10.1016/j.schres.2024.01.022.Peer-Reviewed Original ResearchConceptsCoordinated specialty careDuration of untreated psychosisImpact of early detectionEarly detectionEarly detection campaignsSpecialty careAdjustment scoresCampaign yearDetection campaignsMediation analysisEffects of EDRegression modelsCareUntreated psychosisPositive symptomsGAFPatientsSalutary effects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply